Initially, CAR-T cells were developed for the treatment of acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) [2,3,4]; then, in 2017 two novel CD19-directed CAR-T cell products became commercially available for patients with relapsed/refractory (R/R) aggressive B cell NHL, comprising DLBCL, high-grade B cell lymphoma, primary mediastinal B cell lymphoma (PMBCL), and transformed FL and MCL, after two or more lines of therapy [5]. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.